take, for instance, glaxo smithkline. gsk. british company that's diversified, has a host of repertoire, cardiovascular, vaccines, diabetes, you name it. now, j&j is not a breakup play. not. although it has a big consumer division it could sell and unlock, and maybe unlock some value. they don't need polydent or tums, everything that i use here. anyway, this is not a catch-up play, like merck, which we talked about yesterday. this stock just hit a new 52-week high. so merck is the catch-up play. j&j is the breakup play. this stock is a dividend play. the american version of this british stock, called the adr, sports a monster 5.8% yield, much bigger than the other names. and they tend to yield anywhere between 3% and 4%. not this baby. i would never recommend a stock simply for the high yield. sometimes that can be a red flag that the danger of the dividend being cut is out there. i think it company could be about to turn the corner. let me tell you why. it's a little bit different story from the others. first of all, glaxo ha